All Stories

U.K. keeps funding for clinical research sites flat through to 2022

Nick Paul Taylor The United Kingdom government is to pump £112 million ($ 160 million) into a network of clinical research facilities from 2017 to 2022. Officials see the investment ...

Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging

John Carroll Imagine a drug that could clear away "senescent" cells and make the life span allotted to you healthier, absent many of the myriad diseases that can accumulate ...

Merck treads water in Q4 as Keytruda helps offset Remicade suffering

Tracy Staton Merck & Co. took a one-two punch in the fourth quarter. Revenue from two top-selling franchises–Januvia and Remicade–slid, dragging overall ...

Proteostasis and AveXis test the troubled IPO waters as biotech valuations wane

Damian Garde A pair of early-stage biotech companies has joined the thinning queue of drug developers trying to go public amid a painful market correction, angling to raise more than ...

New data boosts Novo against Sanofi in insulin-market fight

Carly Helfand Novo Nordisk has some new data in hand that could help a safety advantage make its way onto the label of new drug Tresiba–and win it points against heavyweight ...

Replacing a biotech legend, Gilead’s new CEO inherits sky-high expectations

Damian Garde John Martin, the man who led Gilead Sciences from the basements of biotech to the verge of Big Pharma, is stepping down after 20 years, with longtime lieutenant John Milligan ...

Struggling Eisai gets FDA approval for cancer drug Halaven for liposarcoma

Eric Palmer Japan's Eisai got a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced ...

Genentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen

John Carroll Genentech has moved to the head of a small group of players in the anti-inflammatory arena, bagging rights to an antibody that scrambles the connection between IL-33 and ...

Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie

Carly Helfand Industry watchers have long been speculating on how Merck would take on heavyweights Gilead and AbbVie when it priced its new hep C regimen. And now, they have their answer: ...

Venetoclax grabs third FDA ‘breakthrough’ for blood cancer

Alok Saboo AbbVie and Roche's venetoclax has received yet another accelerated review from the FDA–this time in patients with the most common type of acute leukemia. FierceBiotech ...

The top 10 (possible) blockbusters that (might) launch this year

John Carroll Can't get enough of sell-side estimates on the big new drugs in the late-stage pipeline? Then we have a treat for you today. FierceBiotech News

UPDATED: Big investor to activists: J&J should break up, so please put on the heat

Tracy Staton Should Johnson & Johnson join the Big Pharma split-up club? One of its major shareholders thinks so, and it's pressing activist investors to join the cause. FiercePharma ...
Page 3 of 83912345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS